Haleh Hamedifar, the managing director of Sinagen Co., said that the medication had been developed 3 years ago, and according to the regulations, it was legal to export medication. “Sinovex is an MS (Multiple Sclerosis) medication developed by the company and supplies the medication to 50-60 per cent of the domestic demand,” said she. “Sinagen is also capable of meeting the needs of the whole region as well; Russia, Armenia, Azerbaijan, Pakistan and Syria are major importers of the drug,” she asserted.
“The company was awarded ISO quality management standard certification; we also received consumer rights standard award and GMP standard,” Haleh Hamedifar added.
She said that it was important for company to allocate 20 per cent of income to research and development, since “it directly contributes to production levels.”
Hamedifar said that the company has only recently did receive financial support from the Ministry of Industries; and it went under the umbrella of Biotechnology Headquarters of President’s Science and Technology Deputy; “Currently, the Headquarters communicates to us the priorities and needs to work on; they provide us also with some support in marketing the product,” she added.
“Sinagen should employ highly expert human labor force; if situation demands and favors, the company would welcome university graduates; given the fragile position of economic firms in domestic and foreign competitive markets, the support should be extended to these companies as well,” Hamedifar proposed. “Knowledge-based companies fight giants in the international markets as their rivals; and providing them with support would benefit the country,” she added.
SH
MNA
END